0001213900-25-059797.txt : 20250630 0001213900-25-059797.hdr.sgml : 20250630 20250630173418 ACCESSION NUMBER: 0001213900-25-059797 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250617 FILED AS OF DATE: 20250630 DATE AS OF CHANGE: 20250630 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Smith Ryan Lewis CENTRAL INDEX KEY: 0001619129 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38105 FILM NUMBER: 251093450 MAIL ADDRESS: STREET 1: 1600 BROADWAY STREET 2: SUITE 1360 CITY: DENVER STATE: CO ZIP: 80202 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: 180 Life Sciences Corp. CENTRAL INDEX KEY: 0001690080 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 813832378 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3000 EL CAMINO REAL STREET 2: BLDG 4, STE 200 CITY: PALO ALTO STATE: CA ZIP: 94306 BUSINESS PHONE: 650-507-0669 MAIL ADDRESS: STREET 1: 3000 EL CAMINO REAL STREET 2: BLDG 4, STE 200 CITY: PALO ALTO STATE: CA ZIP: 94306 FORMER COMPANY: FORMER CONFORMED NAME: KBL MERGER CORP. IV DATE OF NAME CHANGE: 20161115 4/A 1 ownership.xml X0508 4/A 2025-06-17 2025-06-20 0 0001690080 180 Life Sciences Corp. ATNF 0001619129 Smith Ryan Lewis 3000 EL CAMINO REAL, BLDG. 4, SUITE 200 PALO ALTO CA 94306 1 0 0 0 0 Common Stock 2025-06-17 4 A 0 102181 0.0 A 167181 D Non-Qualified Stock Option (right to buy) 0.929 2025-06-17 4 A 0 255000 0.0 A 2035-06-17 Common Stock 255000 255000 D Represents restricted stock shares subject to time-based vesting, which vest at the rate of 1/2 of such shares on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. Issued under the Issuer's 2022 Equity Compensation Plan (the "Equity Plan"). Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer. The options vest 1/2 on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. Issued under the Issuer's 2025 Option Incentive Plan. The 2025 Option Incentive Plan is subject to stockholder approval and (i) no options can be exercised prior to obtaining stockholder approval for such plan, and (ii) the outstanding options will be cancelled, if stockholder approval is not obtained. This Form 4/A is being filed to reflect the fact that the number of shares awarded to the Reporting Person was retroactively adjusted by the Board of Directors and Compensation Committee of the Company on June 28, 2025, so that there was sufficient room for such award, and other awards made on the same date, under the Equity Plan. /s/ Ryan Smith 2025-06-30